Hong Kong Stock Movement: PEGBIO CO-B plummets 20.51%, market volatility intensifies, and capital flow attracts attention

Hong Kong Stock Movement PEGBIO CO-B, down 20.51%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Kangfang Biotech, down 3.38%, with a trading volume of HKD 560 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics down 1.55%. Based on recent key news: On May 12, JP Morgan released a research report indicating that the adjustment plan for the drug catalog announced by the National Healthcare Security Administration will improve the commercialization prospects for innovative drug developers. Innovent Biologics is listed as an industry preferred stock, with expected sales growth accelerating, positively impacting the stock price. Source: Zhitong Finance On May 11, Innovent Biologics received breakthrough therapy designation from China's NMPA for the combination treatment of IBI363 and Bevacizumab for colorectal cancer. This designation brings potential market expansion opportunities for the company, causing stock price fluctuations. Source: Zhitong Finance On May 11, BeiGene's BTK inhibitor achieved significant global sales, and the industry saw an increase in external licensing transaction volume. Innovent Biologics, as an innovative drug company, benefits from industry trends. Source: Zhitong Finance. The investment logic in the innovative drug sector shifts towards profitability verification. Jitai Technology-P up 13.61%. Based on recent key news: On May 13, Jitai Technology-P debuted on the Hong Kong Stock Exchange, with the opening price rising 173.1% compared to the offering price. The company's innovative technology in AI nanomaterials attracted market attention, leading to a significant increase in stock price. Source: Zhitong Finance On May 13, the public offering portion of Jitai Technology-P was oversubscribed approximately 6,909 times, showing strong investor confidence in its market potential, further driving up the stock price. Source: Economic Information Daily On May 13, Jitai Technology-P's dark pool trading showed a high opening price of 204.8%, reflecting the market's positive expectations for its listing, further boosting the stock price. Source: Futu Trading Platform. The AI drug delivery sector is gaining attention, with significant capital inflow. Stocks with High Market Capitalization in the Industry BeiGene down 2.82%. Based on recent news: On May 11, BeiGene released its Q1 2026 earnings report, showing the company achieved operating revenue of RMB 10.544 billion, a year-on-year increase of 31%; net profit attributable to the parent company was RMB 1.608 billion, turning from loss to profit year-on-year. The performance change is mainly due to product revenue growth and expense management driving operational efficiency improvements. This news boosted market confidence, but the stock price still experienced fluctuations in the short term. On May 12, BeiGene's stock price closed at HKD 190.5, with an intraday volatility of over 4%. Despite significant fluctuations during the day, the final closing price remained close to the opening price, indicating a temporary balance between bullish and bearish forces. From a technical perspective, the MACD daily line formed a golden cross signal above the zero axis, indicating that bullish forces are gathering again in the previous upward trend On May 13th, BeiGene announced that its new drug Baidueda (sotatercept) received accelerated approval from the U.S. FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. This news creates positive expectations for the company's future performance growth, but the market reaction in the short term is relatively cautious. The overall trading in the pharmaceutical and biotechnology sector is active, and attention should be paid to changes in trading volume